Juno Therapeutics (NASDAQ:JUNO) is developing next-generation cancer therapies that use a patient's own immune system to find and destroy cancer cells.
Although the company doesn't have any drugs currently on the market, it hopes that a promising drug for adult lymphoblastic leukemia will succeed in mid stage studies and clear the way to an FDA filling in 2017.
Given high response rates to its most advanced drug and a timeline that could mean Juno Therapeutics begins generating sales within two years, investors boosted shares by 12.1% last month. In the following slideshow, I offer up additional insight into Juno Therapeutics intriguing approach and its timeline to commercialization.
Todd Campbell is long Celgene. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool recommends Juno Therapeutics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.